Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113363 | 0.91 | MEN1 (0.37) | CTSLCTSSCTSKSCN9AMEN1 | |
| SCHEMBL4160587 | 0.88 | CTSL (0.40) | CTSLCTSSCTSKSCN9AHDAC1 | |
| SCHEMBL4102277 | 0.85 | SCN9A (0.55) | CTSLCTSSCTSKSCN9ACCKBR | |
| SCHEMBL4119690 | 0.85 | SCN9A (0.55) | CTSLCTSSCTSKSCN9ACCKBR | |
| SCHEMBL8251395 | 0.84 | SCN9A (0.45) | CTSLCTSSCTSKSCN9AHDAC1 | |
| SCHEMBL4162896 | 0.84 | CTSL (0.42) | CTSLCTSSCTSKSCN9ATACR1 | |
| SCHEMBL13814414 | 0.81 | TACR1 (0.45) | CTSLCTSSCTSKSCN9AHDAC1 | |
| SCHEMBL4113611 | 0.79 | MEN1 (0.37) | CCKBRMEN1KMT2A | |
| SCHEMBL4167968 | 0.78 | DPP4 (0.45) | SCN9AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4167971 | 0.78 | DPP4 (0.45) | SCN9AMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| EP-1912706-A4 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIE (IN) | 2009-05-27 | — | — | EP | disclosed |
| EP-1912706-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006134613-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | DPP4, DPP3, DPP7 | CTSL 394/4885CTSS 1084/4885CTSK 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.